BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19074063)

  • 1. From palliation to epigenetic therapy in myelofibrosis.
    Rambaldi A; Barbui T; Barosi G
    Hematology Am Soc Hematol Educ Program; 2008; ():83-91. PubMed ID: 19074063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
    Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
    Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
    [No Abstract]   [Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for myelofibrosis in 2012.
    McLornan DP; Mead AJ; Jackson G; Harrison CN
    Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
    [No Abstract]   [Full Text] [Related]  

  • 5. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
    Shanavas M; Gupta V
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing between stem cell therapy and drugs in myelofibrosis.
    Kröger N; Mesa RA
    Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the understanding and management of primary myelofibrosis.
    Cervantes F; Pereira A
    Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Barosi G; Bacigalupo A
    Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
    Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating early-stage myelofibrosis.
    Palandri F; Sabattini E; Maffioli M
    Ann Hematol; 2019 Feb; 98(2):241-253. PubMed ID: 30343328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modern management of myelofibrosis.
    Cervantes F
    Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiology of and therapy for primary myelofibrosis].
    Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
    [No Abstract]   [Full Text] [Related]  

  • 15. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
    Alchalby H; Badbaran A; Bock O; Fehse B; Bacher U; Zander AR; Kröger N
    Bone Marrow Transplant; 2010 Sep; 45(9):1404-7. PubMed ID: 20062088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
    Mesa RA
    Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia.
    Kekre N; Ho VT
    Am J Hematol; 2016 Jan; 91(1):123-30. PubMed ID: 26453238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
    Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
    Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.
    Zang DY; Deeg HJ
    Curr Opin Hematol; 2009 Mar; 16(2):140-6. PubMed ID: 19468277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
    El Fakih R; Popat U
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.